1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year.
Nektar Therapeutics's 1-Year ROIIC % for the quarter that ended in Mar. 2026 was 10.34%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Nektar Therapeutics's 1-Year ROIIC % or its related term are showing as below:
FRA:ITH0's 1-Year ROIIC % is ranked better than 60.78% of 1341
companies
in the Biotechnology industry
Industry Median: -8.77
vs FRA:ITH0: 10.34
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Nektar Therapeutics 1-Year ROIIC % Related Terms
Nektar Therapeutics 1-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Nektar Therapeutics's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ITH0 vs OCUL, PVLA, GENB: 1-Year ROIIC % Comparison
For the Biotechnology subindustry, Nektar Therapeutics's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nektar Therapeutics 1-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Nektar Therapeutics's 1-Year ROIIC % falls into.
Nektar Therapeutics's 1-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
1-Year ROIIC %
=
1-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
1-Year Incremental Invested Capital
=
( -107.1119 (Mar. 2026) - -129.408 (Mar. 2025) )
/
( 174.53 (Mar. 2026) - 49.206 (Mar. 2025) )
=
22.2961
/
125.324
=
17.79%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Nektar Therapeutics (FRA:ITH0) has a 1-Year ROIIC % of 10.34 as of Mar. 2026. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Nektar Therapeutics and its competitors. According to the industry distribution chart, Nektar Therapeutics ranks #526 out of 1341 companies in the Biotechnology industry, placing it in the top 39.2%.
Is Nektar Therapeutics' 1-Year ROIIC % too high?
Nektar Therapeutics' current 1-Year ROIIC % is 10.34. Based on the distribution chart, Nektar Therapeutics ranks #526 out of 1341 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nektar Therapeutics has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nektar Therapeutics' 1-Year ROIIC % compare to OCUL and PVLA?
According to the Biotechnology industry distribution chart, Nektar Therapeutics ranks #526 out of 1341 companies for 1-Year ROIIC %. This puts Nektar Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Biotechnology company?
A good 1-Year ROIIC % depends on the Biotechnology industry context. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Nektar Therapeutics and its competitors. Nektar Therapeutics's current 1-Year ROIIC % is 10.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nektar Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nektar Therapeutics (FRA:ITH0) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.18, compared to a current price of €62.66 — trading 1109.7% above its estimated fair value. The current 1-Year ROIIC % is 10.34. Nektar Therapeutics' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Nektar Therapeutics (FRA:ITH0), the current 1-Year ROIIC % is 10.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nektar Therapeutics (FRA:ITH0) Overvalued in 2026?
Based on GuruFocus' analysis, Nektar Therapeutics stock appears to be overvalued.
The current stock price of €62.66 is trading 1109.7% above its estimated GF Value™ of €5.18.
GuruFocus considers Nektar Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:ITH0:
1-Year ROIIC %: 10.34
GF Value™: €5.18 vs. price of €62.66 (1109.7% above fair value)
No single metric tells the full story. See the FRA:ITH0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
47GF Score
Get the complete analysis for FRA:ITH0
1-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ITH0 has been successfully added to your 
